AI Spatial Biology startup Nucleai secured $33 Million in Series B Round


Nucleai, an Israel based AI-powered spatial biology company, has now secured $33 million in a Series B funding round.

Nucleai is founded by Avi Weidman. It offers pharmaceutical companies, contract research organizations, diagnostics laboratories with an AI platform to improve clinical trials and clinical decision making.

The platform is used for retrospective and prospective patient satisfaction analysis in clinical trials, driving improvement of the probability of success and improved patient outcomes.

Executive Opinion

Avi Veidman, CEO of Nucleai, said, "Nucleai’s vision is to bring spatial biology to the forefront of precision medicine and to embed the use of our platform in every clinical trial involving tissue over the next few years. We are pleased to bring world-class investors who share our passion and vision to transform drug development and clinical treatment decisions by combining artificial intelligence, big data, spatial biology, and a comprehensive software platform."

Cris De Luca, Global Head, Digital Investments at Sanofi Ventures, said, "The rapid growth and achievements of the Nucleai team have them well-positioned to be spatial biology platform leaders, transforming current approaches to pathology. By harnessing artificial intelligence with spatial data and other data modalities, Nucleai is enabling researchers and clinicians to make better treatment decisions for patients based on a comprehensive, holistic view of cellular locations, interactions, and the tumour microenvironment."

Nucleai's Latest Funding

The round was backed by Sanofi Ventures and Section 32 with participation from Debiopharm, Vertex Ventures, Fosun RZ Capital, and Grove Ventures.

The company, as of now, has plans to use the new funds to further develop its platform and expand its commercial footprint across the biopharmaceutical companies and contract research organizations (CROs), who are applying its technology throughout translational research, novel applications and clinical trials for drug discovery.
PC: Pixabay

Note: We at TechSutram take our ethics very seriously. More information about it can be found here.
Udit Agarwal Opinions expressed by techsutram contributors are their own. More details

Udit Agarwal is a Digital Marketer and a Content Marketing Specialist, He enjoys technical as well as non-technical writing. His passion and urge for gaining new insights on gadgets, smartphones and technology has led him to Techsutram. He quenches his thirst for technology through his action oriented writing skills and a profound ability to stay up to date with latest industry trends.

No comments:

Post a Comment

    Your valuable comments are welcome. (Moderated)